WOBURN, MA—January 23, 2006—Covaris, Inc. a privately held company founded in 1999 to develop instrument systems based on its patented, proprietary, biophysical technology platform, today announced a new series of new acoustic-based instruments ready for incorporation into a wide array of scientific disciplines. The C2000 will be introduced at the LabAutomation 2006 trade show held in Palm Springs, California.
The C2000, the first of a new instrument series from Covaris, will be particularly beneficial to the Compound Management departments of the pharmaceutical industry. According to James Laugharn, President, Covaris, “The system will be an invaluable aid to ensure compounds selected from large central storage facilities, sometimes holding millions of individual vials of individual compounds, will be dissolved, solvated, redissolved, or uniformly suspended prior to downstream analysis.” By providing a non-contact, rapid process to actively control the solubilization status of a target compound, the potential to improve the reliability of downstream processes (such as high-throughput screening) improves.
The new instrument series will incorporate the Adaptive Focused Acoustics (AFA) technology developed by Covaris. The AFA process enables self-configuring processes to be readily developed for diverse sample types. This results in rapid and uniform sample processing and the resultant benefit is improved sample preparation control.
Covaris, Inc. is a privately held company founded in 1999 to develop instrument systems based on its proprietary, patent-pending, biophysical technology platform. The technology is based on focused acoustic energy and applications of shock wave physics for advanced and high-throughput applications in biology and medicine.
14 Gill Street, Unit H
Tel: +1 781-932-3959
Fax: +1 781-932-8705